The disease duration ranged from 0.33 to 312 months with a mean duration of 64.44 months. The starting dose of IG-001 was 300 mg/m². The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). In the US and EUI it is being developed under the name of CynVax®.

Other (25%) Cancer Mortality- Female
(56% coverage with IG-001)

- 4% Breast
- 3% Bladder
- 3% NHL
- 3% Prostate
- 10% Lung
- 8% Colorectal
- 6% Pancreatic
- 4% Liver
- 4% Leukemia
- 4% Esophageal
- 3% Other

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².

For the 710 TEAEs, 730 (43.24%) were Grade 1 in severity, 252 (35.49%) were Grade 2, 151 (21.96%) were Grade 3, 55 (7.75%) were Grade 4 and 2 (0.28%) were Grade 5. Of the 364 evaluable subjects, 50.31% were women. The results of the efficacy assessments showed that 36/148 evaluable subjects were CR (complete response) and PR (partial response). The starting dose of IG-001 was 300 mg/m².